The PKCβ/HuR/VEGF pathway in diabetic retinopathy

Biochemical Pharmacology

Volumn 80, Issue 8, 2010, Pages 1230-1237

  Amadio, M ^a   Bucolo, C ^b   Leggio, G M ^b   Drago, F ^b   Govoni, S ^a   Pascale, A ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Diabetes; Embryonic lethal abnormal vision protein; PKC; Retina; VEGF

Indexed keywords

EMBRYONIC LETHAL ABNORMAL VISION PROTEIN; GLUCOSE; HUR PROTEIN; MESSENGER RNA; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C BETA1; PROTEIN KINASE C BETA2; RIBONUCLEOPROTEIN; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ELAV-LIKE PROTEIN 1; MEMBRANE ANTIGEN; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; IMMUNOPRECIPITATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; UPREGULATION; WESTERN BLOTTING; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RETINA; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, SURFACE; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; MALE; PHOSPHORYLATION; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RNA-BINDING PROTEINS;

EID: 77956226516     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.033     Document Type: Article

References (65)

1. Wilkinson-Berka J.L., Miller A.G. Update on the treatment of diabetic retinopathy. Sci World J 2008, 8:98-120.
2. Porta M., Bandello F. Diabetic retinopathy. A clinical update. Diabetologia 2002, 45:1617-1634.
3. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009, 29:789-791.
4. Adamis A.P., Shima D.T. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005, 25:111-118.
5. Michaelson I.C. Vascular morphogenesis in the retina of the cat. J Anat 1948, 82:167-174.
6. Wirostko B., Wong T.Y., Simó R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008, 27:608-621.
7. Penn J.S., Madan A., Caldwell R.B., Bartoli M., Caldwell R.W., Hartnett M.E. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008, 27:331-371.
8. Ye X., Xu G., Chang Q., Fan J., Sun Z., Qin Y., et al. ERK1/2 signaling pathways involved in VEGF release in diabetic rat retina. Invest Ophthalmol Vis Sci 2010, (May). [Epub ahead of print].
9. Yokota T., Utsunomiya K., Taniguchi K., Gojo A., Kurata H., Tajima N. Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina. Jpn J Ophthalmol 2007, 51:424-430.
10. Clarke M., Dodson P.M. PKC inhibition and diabetic microvascular complications. Best Pract Res Clin Endocrinol Metab 2007, 21:573-586.
11. Pascale A., Amadio M., Govoni S., Battaini F. The aging brain, a key target for the future: the protein kinase C involvement. Pharmacol Res 2007, 55:560-569.
12. Amadio M., Govoni S., Alkon D.L., Pascale A. Emerging targets for the pharmacology of learning and memory. Pharmacol Res 2004, 50:111-122.
13. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859-866.
14. Idris I., Gray S., Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001, 44:659-673.
15. Aiello L.P. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002, 47:S263-269.
16. Das Evcimen N., King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007, 55:498-510.
17. Kim Y.H., Kim Y.S., Park C.H., Chung I.Y., Yoo J.M., Kim J.G., et al. Protein kinase C-delta mediates neuronal apoptosis in the retinas of diabetic rats via the Akt signaling pathway. Diabetes 2008, 57:2181-2190.
18. Amadio M., Scapagnini G., Lupo G., Drago F., Govoni S., Pascale A. PKCbetaII/HuR/VEGF: a new molecular cascade in retinal pericytes for the regulation of VEGF gene expression. Pharmacol Res 2008, 57:60-66.
19. Pascale A., Amadio M., Quattrone A. Defining a neuron: neuronal ELAV proteins. Cell Mol Life Sci 2008, 65:128-140.
20. Bolognani F., Perrone-Bizzozero N.I. RNA-protein interactions and control of mRNA stability in neurons. J Neurosci Res 2008, 86:481-489.
21. Levy A.P., Levy N.S., Goldberg M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996, 271:2746-2753.
22. Levy N.S., Chung S., Furneaux H., Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998, 273:6417-6423.
23. Tang K., Breen E.C., Wagner P.D. Hu protein R-mediated posttranscriptional regulation of VEGF expression in rat gastrocnemius muscle. Am J Physiol Heart Circ Physiol 2002, 283:H1497-1504.
24. Lejbkowicz F., Goldberg-Cohen I., Levy A.P. New horizons for VEGF. Is there a role for nuclear localization?. Acta Histochem 2005, 106:405-411.
25. Slosberg E.D., Yao Y., Xing F., Ikui A., Jirousek M.R., Weinstein I.B. The protein kinase C beta-specific inhibitor LY379196 blocks TPA-induced monocytic differentiation of HL60 cells. Mol Carcinog 2000, 27:166-176.
26. Pascale A., Fortino I., Govoni S., Trabucchi M., Wetsel W.C., Battaini F. Differential isoform-specific regulation of calcium-independent protein kinase C in rat cerebral cortex. Neurosci Lett 1996, 214:99-102.
27. Ron D., Jiang Z., Yao L., Vagts A., Diamond I., Gordon A. Coordinated movement of RACK1 with activated betaII PKC. J Biol Chem 1999, 274:27039-27046.
28. Pascale A., Gusev P.A., Amadio M., Dottorini T., Govoni S., Alkon D.L., et al. Increase of the RNA-binding protein HuD and posttranscriptional up-regulation of the GAP-43 gene during spatial memory. Proc Natl Acad Sci USA 2004, 101:1217-1222.
29. Pascale A., Amadio M., Scapagnini G. Neuronal ELAV proteins enhance mRNA stability by a PKCalpha-dependent pathway. Proc Natl Acad Sci USA 2005, 102:12065-12070.
30. Patel R., Pariente J.A., Martinez M.A., Salido G.M., Singh J. Effect of insulin on acetylcholine-evoked amylase release and calcium mobilization in streptozotocin-induced diabetic rat pancreatic acinar cells. Ann N Y Acad Sci 2006, 1084:58-70.
31. Ishii H., Jirousek M.R., Koya D. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996, 272:728-731.
32. Liu Y., Su W., Thompson E.A., Leitges M., Murray N.R., Fields A.P. Protein kinase Cbeta II regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem 2004, 279:45556-45563.
33. Kusari J., Zhou S.X., Padillo E., Clarke K.G., Gil D.W. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Invest Ophthalmol Vis Sci 2010, 51:1044-1051.
34. Xu X., Zhu Q., Xia X., Zhang S., Gu Q., Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res 2004, 28:251-256.
35. Cohen M.P., Hud E., Wu V.Y., Shearman C.W. Amelioration of diabetes-associated abnormalities in the vitreous fluid by an inhibitor of albumin glycation. Invest Ophthalmol Vis Sci 2008, 49:5089-5093.
36. DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
37. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
38. Suzuma K., Takahara N., Suzuma I. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 2002, 99:721-726.
39. Ohshiro Y., Ma R.C., Yasuda Y. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase C beta-null mice. Diabetes 2006, 55:3112-3120.
40. Kim Y.H., Kim Y.S., Kang S.S. Expression of 14-3-3 zeta and interaction with protein kinase C in the rat retina in early diabetes. Diabetologia 2005, 48:1411-1415.
41. Xia Z., Kuo K.H., Nagareddy P.R. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 2007, 73:770-782.
42. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Cox A.J., Qi W., et al. Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy: relationship to long-term glycaemic control. Diabetologia 2008, 51:668-674.
43. Joussen A.M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Döhmen S., et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNFα suppression. FASEB J 2002, 16:438-440.
44. Aiello L.P., Bursell S.E., Clermont A., Duh E., Ishii H., Takagi C., et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480.
45. Budhiraja S., Singh J. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. Fundam Clin Pharmacol 2008, 22:231-240.
46. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008, 41:278-286.
47. Simó R., Carrasco E., García-Ramírez M., Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006, 2:71-98.
48. Barreau C., Paillard L., Osborne H.B. AU-rich elements and associated factors: are there unifying principles?. Nucleic Acids Res 2006, 33:7138-7150.
49. Short S., Tian D., Short M.L., Jungmann R.A. Structural determinants for post-transcriptional stabilization of lactate dehydrogenase A mRNA by the protein kinase C signal pathway. J Biol Chem 2000, 275:12963-12969.
50. Rossi D., Amadio M., Carnevale Baraglia A., Azzolina O., Ratti A., Govoni S., et al. Discovery of small peptides derived from embryonic lethal abnormal vision proteins structure showing RNA-stabilizing properties. J Med Chem 2009, 52:5017-5019.
51. Wells D.G. RNA-binding proteins: a lesson in repression. J Neurosci 2006, 26:7135-7138.
52. Keene J.D. Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. Proc Natl Acad Sci USA 1999, 96:5-7.
53. Hammes H.P., Lin J., Bretzel R.G., Brownlee M., Breier G. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998, 47:401-406.
54. Wang K., Wang Y., Gao L., Li X., Li M., Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 2008, 31:1541-1546.
55. Gerhardinger C., Costa M.B., Coulombe M.C., Toth I., Hoehn T., Grosu P. Expression of acute-phase response proteins in retinal Müller cells in diabetes. Invest Ophthalmol Vis Sci 2005, 46:349-357.
56. Brucklacher R.M., Patel K.M., VanGuilder H.D., Bixler G.V., Barber A.J., Antonetti D.A., et al. Whole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory response. BMC Med Genomics 2008, 1:26.
57. Chung H.K., Choi S.M., Ahn B.O., Kwak H.H., Kim J.H., Kim W.B. Efficacy of troxerutin on streptozotocin-induced rat model in the early stage of diabetic retinopathy. Arzneimittelforschung 2005, 55:573-580.
58. Amadio M., Scapagnini G., Laforenza U. Post-transcriptional regulation of HSP70 expression following oxidative stress in SH-SY5Y cells: the potential involvement of the RNA-binding protein HuR. Curr Pharm Des 2008, 14:2651-2658.
59. Danilin S., Sourbier C., Thomas L., Lindner V., Rothhut S., Dormoy V., et al. Role of the RNA-binding protein HuR in human renal cell carcinoma. Carcinogenesis 2010, 31:1018-1026.
60. McMullen M.R., Cocuzzi E., Hatzoglou M., Nagy L.E. Chronic ethanol exposure increases the binding of HuR to the TNFalpha 3'-untranslated region in macrophages. J Biol Chem 2003, 278:38333-38341.
61. Gantt K.R., Cherry J., Richardson M., Karschner V., Atasoy U., Pekala P.H. The regulation of glucose transporter (GLUT1) expression by the RNA binding protein HuR. J Cell Biochem 2006, 99:565-574.
62. Ayalasomayajula S.P., Ashton P., Kompella U.B. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther 2009, 25:97-103.
63. Kim J.H., Kim J.H., Jun H.O., Yu Y.S., Kim K.W. Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy. Am J Pathol 2010, 176:1517-1524.
64. Antonetti D.A., Barber A.J., Khin S., Lieth E., Tarbell J.M., Gardner T.W. Vascular permeability in experimental diabetes associated with reduced endothelial occludin content. Diabetes 1998, 47:1953-1959.
65. Podar K., Tai Y.T., Lin B.K., Narsimhan R.P., Sattler M., Kijima T., et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 2002, 277:7875-7881.